Menu
Search
|

Menu

Close
X

Urogen Pharma Ltd URGN.OQ (NASDAQ Stock Exchange Global Market)

41.93 USD
-- (--)
As of Oct 19
chart
Previous Close 41.93
Open --
Volume --
3m Avg Volume 26,916
Today’s High --
Today’s Low --
52 Week High 68.91
52 Week Low 25.58
Shares Outstanding (mil) 13.01
Market Capitalization (mil) 381.96
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.33 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
8
FY16
18
FY15
0
EPS (USD)
FY18
-2.018
FY17
-3.172
FY16
-6.122
FY15
-0.874
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
--
5.83
Price to Book (MRQ)
vs sector
5.16
4.89
Price to Cash Flow (TTM)
vs sector
--
22.92
Total Debt to Equity (MRQ)
vs sector
0.00
17.18
LT Debt to Equity (MRQ)
vs sector
0.00
12.76
Return on Investment (TTM)
vs sector
--
14.27
Return on Equity (TTM)
vs sector
--
15.99

EXECUTIVE LEADERSHIP

Arie Belldegrun
Chairman of the Board, Since 2012
Salary: --
Bonus: --
Ron Bentsur
Chief Executive Officer, Director, Since 2015
Salary: --
Bonus: --
Peter Pfreundschuh
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Gil Hakim
President - Israeli Operation, Since 2015
Salary: --
Bonus: --
Stephen Mullennix
Chief Operating Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9 Ha'Ta'asiya St
RA'ANANA     4365007

Phone: +9729.7707600

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.

SPONSORED STORIES